Study summary
Two immunotherapies kept most MSI-high metastatic cancers in check for 2 years
72%without progression at 2 years, vs 14% with chemotherapy
What was tested
Nivolumab plus ipilimumab against chemotherapy as first treatment for metastatic MSI-high or dMMR colorectal cancer.
What they found
- 24-month progression-free survival was 72% vs 14%.
- Severe side effects were less common (23% vs 48%).
What it means
Immunotherapy is now the first treatment for MSI-high metastatic colorectal cancer.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.